Daliresp

Daliresp, also known by its generic name roflumilast, is a medication used to treat severe exacerbations of chronic obstructive pulmonary disease (COPD). It belongs to a class of drugs called phosphodiesterase-4 (PDE4) inhibitors. Roflumilast works by reducing inflammation in the airways, which is a key factor in COPD exacerbations. It is typically prescribed in addition to other COPD maintenance therapies, such as bronchodilators, and is not intended for use as a rescue inhaler.

The medication is taken orally as a tablet once a day. It is important for patients to take Daliresp exactly as prescribed by their healthcare provider and to not stop taking it without consulting their doctor. Common side effects associated with Daliresp can include diarrhea, nausea, weight loss, and headache. Less common but more serious side effects may occur, and patients should report any concerning symptoms to their doctor immediately.

Daliresp is generally not recommended for individuals with moderate to severe liver impairment. It is crucial for patients to inform their doctor about any pre-existing medical conditions, especially liver problems, and any other medications they are currently taking, as there can be potential drug interactions. The effectiveness and safety of Daliresp have been established through clinical trials, and it plays a role in managing a specific aspect of severe COPD by targeting airway inflammation.